Pomdoctor is a Guangzhou internet-hospital and drug-wholesale operator that reached Nasdaq last October and spent the following year proving that a listing does not convert a thin-margin pharmacy business into a funded growth story. The fiscal year that closed at year-end showed mid-teens revenue growth and a collapse in cash conversion. Initial-offering proceeds arrived, operating cash outflow exploded, and the successor auditor attached a going-concern paragraph. Management now markets an artificial-intelligence wearable and membership upgrade that does not appear as a disclosed revenue line in the audited year. The investment debate is whether the remaining equity is a call on a real chronic-disease pharmacy platform that can stop burning cash, or a listing vehicle whose operating economics cannot support the story being sold to conference audiences.
Internet hospital sales nearly doubled as manufacturer pharmacy volume moved onto the platform, yet that mix shift pulled the hospital gross margin down by ten points and left consultation fees as a rounding error. The wholesale chain, still the larger revenue engine, shrank slightly and printed a one-percent-range gross margin after the company walked away from longer-credit customers and closed two stores. Combined operating expenses more than doubled, with investor-relations consulting and brand-promotion fees alone absorbing a large share of the offering cash. Year-end cash sat near $1 million after an operating outflow above $21 million. That is not a temporary listing hangover. It is a business that consumes more cash than it earns in gross profit.
Nasdaq closed the bid-price file in July after a one-for-eighteen American depositary share consolidation lifted the quote back above the exchange floor. The same summer produced an auditor switch, an amended securities complaint in New York federal court over the post-offering price collapse, and a roadshow plan that contemplates a $30 million raise against a mid-single-digit-million equity value. Half-year figures for the current fiscal year have not reached the public record. The next interim either shows the pharmacy mix stabilizing and the cash burn slowing, or the company has to sell a large slice of a tiny float to keep the listing and the artificial-intelligence narrative alive.